

#3 Unravelling Organ Crosstalk in Cardiorespiratory and Neurological Diseases

Proposal for symposium

Applicant details:			
Name:	[REDACTED]		
Affiliation:	[REDACTED]		
Address:	[REDACTED]		
Phone:	[REDACTED]	Email:	[REDACTED]

Symposium details:	
Symposium title:	Unravelling Organ Crosstalk in Cardiorespiratory and Neurological Diseases
Are there specific Special Interest Groups (SIG) and/or external societies involved in the symposium? Please name:	The symposium will bring together speakers and members from THREE ASCEPT SIGs including the Respiratory and Inflammation, Cardiovascular and Neuropharmacology SIGs.
Audience profile, including any anticipated cross-SIG interest:	Broad appeal to members of ASCEPT from fundamental pharmacology to clinical pharmacology, drug delivery and experimental models to assess pharmacological agents.
Descriptive summary of the symposium (abstract) (100–200 words). If the symposia aligns with the meeting theme, Transformational Pharmacology and Toxicology, please indicate how within the proposal. Note that alignment isn't necessary for acceptance in the ASM.	<p>Transformational Pharmacology can only occur with state-of-the-art preclinical models of disease and taking into consideration organ crosstalk in disease and drug development. Inflammation is important in maintaining homeostasis, and can occur locally (i.e. in a specific organ) and/or systemically (i.e. in blood/lymphatics). However, in many chronic diseases unresolved low-grade chronic inflammation can be disease-causing and can exacerbate disease.</p> <p>For this symposium, we have combined experts in organ crosstalk in cardio- respiratory and neurological diseases. This session will showcase important pharmacotherapies targeting inflammatory responses in cardiorespiratory and neurological diseases with a key focus on organ crosstalk in these diseases (including heart/lung, lung/brain, heart/kidney axes). We will cover how understanding these processes has been enhanced by advances in preclinical models of disease assessing organ-to-organ axes, and how pharmacologically targeting these processes is a new approach for these intractable diseases.</p> <p>This proposal is clearly in line with this year's conference theme of "<i>Transformational Pharmacology and Toxicology</i>" and brings together a series of presentations that will describe novel models of disease and new transformational pharmacotherapies for</p>

	these conditions, including heart/kidney disease [REDACTED] cardiorespiratory disease [REDACTED], lung and <i>in utero</i> exposures affecting lung/brain [REDACTED].
Brief statement about how your proposed symposium addresses the goals of equity, diversity and inclusion to meet ASCEPT's commitment to balancing representation across their activities in alignment with the diverse composition of their membership. (e.g. through the consideration of symposium speakers, chairs etc.)	This symposium embraces diversity, equity, and inclusion to create a collegial, collaborative, and successful platform to disseminate cutting-edge research. We are committed to achieving equity and inclusion through a balanced representation of male and female contributors (2x male, 2x female Professors), ethnicity, career level (early/mid-career chairs through to senior presenters) and geographical locations (Victoria, NSW).
Potential sources of sponsorship (list organisation name and contact details and advise who will contact them). It is expected that symposia organisers will seek support for invited speakers.	[REDACTED] The organisers will contact these potential sponsors.

Proposed Chairperson(s):	
Name (including academic title):	[REDACTED]
Position title:	[REDACTED]
Affiliation:	[REDACTED]
Country:	[REDACTED]
Email:	[REDACTED]
Society member?	<input checked="" type="checkbox"/> ASCEPT <input type="checkbox"/> NON-MEMBER

Proposed Chairperson(s):	
Name (including academic title):	[REDACTED]
Position title:	[REDACTED]
Affiliation:	[REDACTED]
Country:	[REDACTED]
Email:	[REDACTED]
Society member?	<input checked="" type="checkbox"/> ASCEPT <input type="checkbox"/> NON-MEMBER

Proposed Speaker 1:	
Name (including academic title):	[REDACTED]
Position title:	[REDACTED]
Affiliation:	[REDACTED]
Country:	[REDACTED]
Email:	[REDACTED]
Draft presentation title:	Novel pharmacological interventions to treat hypertension
Society member?	X ASCEPT <input type="checkbox"/> NON-MEMBER
Agreement:	X The speaker has agreed to participate in the symposium if accepted for the program

Proposed Speaker 2:	
Name (including academic title):	[REDACTED]
Position title:	[REDACTED]
Affiliation:	[REDACTED]
Country:	[REDACTED]
Email:	[REDACTED]
Draft presentation title:	Air Pollution-induced respiratory complications: what about the heart?
Society member?	<input type="checkbox"/> ASCEPT X NON-MEMBER
Agreement:	X The speaker has agreed to participate in the symposium if accepted for the program

Proposed Speaker 3:	
Name (including academic title):	[REDACTED]
Position title:	[REDACTED]
Affiliation:	[REDACTED]
Country:	[REDACTED]
Email:	[REDACTED]
Draft presentation title:	Novel mRNA nanoparticles to treat lung cancer
Society member?	X ASCEPT <input type="checkbox"/> NON-MEMBER
Agreement:	X The speaker has agreed to participate in the symposium if accepted for the program

Proposed Speaker 4:	
Name (including academic title):	[REDACTED]
Position title:	[REDACTED]
Affiliation:	[REDACTED]
Country:	[REDACTED]
Email:	[REDACTED]
Draft presentation title:	<i>In utero</i> exposure impacts on neurological disease
Society member?	<input type="checkbox"/> ASCEPT <input checked="" type="checkbox"/> NON-MEMBER
Agreement:	X The speaker has agreed to participate in the symposium if accepted for the program

#15 Pharmacoepidemiology across the lifespan

Proposal for symposium

Applicant details:			
Name:	[REDACTED]		
Affiliation:	[REDACTED]		
Address:	[REDACTED]		
Phone:	[REDACTED]	Email:	[REDACTED]

Symposium details:	
Symposium title:	Pharmacoepidemiology across the lifespan
Are there specific Special Interest Groups (SIG) and/or external societies involved in the symposium? Please name:	ASCEPT Pharmacoepidemiology SIG ASCEPT Clinical Pharmacology SIG ASCEPT Toxicology SIG
Audience profile, including any anticipated cross-SIG interest:	The audience will include academics, researchers, clinicians, regulators and industry with an interest in pharmacoepidemiology and transdisciplinary research to inform clinical pharmacology and toxicology in special populations. This would be of interest to members across SIGs including Pharmacoepidemiology, Clinical Pharmacology and Toxicology SIGs.
Descriptive summary of the symposium (abstract) (100–200 words). If the symposia aligns with the meeting theme, Transformational Pharmacology and Toxicology, please indicate how within the proposal. Note that alignment isn't necessary for acceptance in the ASM.	<p>Australia's National Medicines Policy aims to ensure consumers have fair and timely access to safe and effective medicines. However, patients at the extremes of age (paediatrics and older adults) are often excluded from clinical trials, and may be prescribed medicines not supported by high quality evidence. Pharmacoepidemiological studies are thus important for informing prescribing decisions in these populations, including assessing patterns of medication use and helping evaluate longer-term safety and effectiveness in real-world clinical settings.</p> <p>This symposium will explore the unique perspectives, challenges and opportunities for conducting pharmacoepidemiology research in special populations across the lifespan. Expert speakers will share their experiences and views researching in diverse age groups, including children, neonates, midlife and older adults, and discuss topics such as defining clinically relevant questions, identifying and utilising available datasets, applying epidemiological methods to clinical pharmacology and therapeutics and toxicology research, forming collaborations and linking research to inform policy and practice.</p> <p>The presenters will collectively update ASCEPT members on key aspects of pharmacoepidemiology across the lifespan. The symposium aligns closely with the meeting theme,</p>

	Transformational Pharmacology and Toxicology, as it addresses key issues related to research, practice and policy in this important area.
Brief statement about how your proposed symposium addresses the goals of equity, diversity and inclusion to meet ASCEPT's commitment to balancing representation across their activities in alignment with the diverse composition of their membership. (e.g. through the consideration of symposium speakers, chairs etc.)	<p>Our proposed symposium is comprised of speakers and chairs from a diversity of backgrounds.</p> <p>Speakers are diverse in:</p> <ul style="list-style-type: none"> - Sex and gender - Background (mix of clinician researchers: 2 pharmacists, 1 paediatrician) - Career stage (1 early, 1 mid, 2 senior) - SIG membership (Pharmacoepidemiology, Clinical Pharmacology, Toxicology) <p>Chairs are diverse in:</p> <ul style="list-style-type: none"> - Sex and gender (1 male, 1 female) - Career stage (1 early, 1 mid) - Background (pharmacists, pharmacoepidemiology, aged care, health services research) - Society membership (ISTAART, ASCEPT, APSA, BPS).
Potential sources of sponsorship (list organisation name and contact details and advise who will contact them). It is expected that symposia organisers will seek support for invited speakers.	

Proposed Chairperson(s):	
Name (including academic title):	[REDACTED]
Position title:	[REDACTED]
Affiliation:	[REDACTED]
Country:	[REDACTED]
Email:	[REDACTED]
Society member?	<input checked="" type="checkbox"/> ASCEPT <input type="checkbox"/> NON-MEMBER
Name (including academic title):	[REDACTED]
Position title:	[REDACTED]
Affiliation:	[REDACTED]
Country:	[REDACTED]
Email:	[REDACTED]
Society member?	<input checked="" type="checkbox"/> ASCEPT <input type="checkbox"/> NON-MEMBER

Proposed Speaker 1:	
Name (including academic title):	[REDACTED]
Position title:	[REDACTED]
Affiliation:	[REDACTED]
Country:	[REDACTED]
Email:	[REDACTED]
Draft presentation title:	Paediatric pharmacoepidemiology: starting to come of age
Society member?	<input checked="" type="checkbox"/> ASCEPT <input type="checkbox"/> NON-MEMBER
Agreement:	<input checked="" type="checkbox"/> The speaker has agreed to participate in the symposium if accepted for the program

Proposed Speaker 2:	
Name (including academic title):	[REDACTED]
Position title:	[REDACTED]
Affiliation:	[REDACTED]
Country:	[REDACTED]
Email:	[REDACTED]
Draft presentation title:	Perinatal pharmacoepidemiology
Society member?	<input type="checkbox"/> ASCEPT <input checked="" type="checkbox"/> NON-MEMBER
Agreement:	<input checked="" type="checkbox"/> The speaker has agreed to participate in the symposium if accepted for the program

Proposed Speaker 3:	
Name (including academic title):	[REDACTED]
Position title:	[REDACTED]
Affiliation:	[REDACTED]
Country:	[REDACTED]
Email:	[REDACTED]
Draft presentation title:	Pharmacoepidemiology in adult populations: a focus on prescription opioids
Society member?	<input checked="" type="checkbox"/> ASCEPT <input type="checkbox"/> NON-MEMBER
Agreement:	<input checked="" type="checkbox"/> The speaker has agreed to participate in the symposium if accepted for the program

Proposed Speaker 4:	
Name (including academic title):	[REDACTED]
Position title:	[REDACTED]
Affiliation:	[REDACTED]
Country:	[REDACTED]
Email:	[REDACTED]
Draft presentation title:	Geriatric pharmacoepidemiology: opportunities and challenges
Society member?	<input checked="" type="checkbox"/> ASCEPT <input type="checkbox"/> NON-MEMBER
Agreement:	<input checked="" type="checkbox"/> The speaker has agreed to participate in the symposium if accepted for the program